Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility

1 Jun 2018

Money to be spent on augmenting capability and capacity for process development and scale up, handling of potent substances, crystallization studies and solid phase characterization.

Cambrex is to commence a $5 million expansion of laboratory facilities at its Karlskoga, Sweden site, to augment capability and capacity for process development and scale up, handling of potent substances, crystallization studies and solid phase characterization. Construction work on the three storey, 600-m2 building will commence at the end of Q2 2018, with completion due in Q2 2019.

Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility

The expansion will create space for a new technical laboratory with walk-in hoods for large scale laboratory syntheses up to 10 L, where engineers and chemists will undertake tech transfer studies. The new investment will also enable handling of potent substances at a large laboratory scale, high pressure reactions and parallel synthesis for API route scouting and development.

In addition to the technical laboratory, the expansion will feature two analytical development and quality control laboratories and additional office space for 12 additional scientists and chemists, taking the total headcount to 60.

“We have a rich history in chemistry at our Karlskoga site, dating back 120 years to Alfred Nobel himself in 1896,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. He added: “The new laboratory expansion will enhance our ability to provide global customers with scientific and chemical excellence.”

In 2017 Cambrex announced that it had upgraded its continuous flow capabilities in Karlskoga with a dedicated commercial-scale unit, capable of producing multiple metric tons of high purity API intermediates per annum. To complement these capabilities, the company also completed the installation of multiple continuous flow reactor platforms at its process development facility in High Point, North Carolina. This investment is focused on the rapid and successful development of processes to supply clinical as well as commercial demand for chemical syntheses.

Read More

Companies mentioned

Related tags

Market News

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more